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Rationale: Plasma soluble Receptor for Advanced Glycation End Product (sRAGE) is considered as a biomarker in
COPD. The contribution of endogenous sRAGE (esRAGE) to the pool of plasma sRAGE and the implication of both
markers in COPD pathogenesis is however not clear yet. The aim of the current study was therefore to measure
plasma levels of esRAGE comparative to total sRAGE in patients with COPD and a control group. Further, we
established the relations of esRAGE and total sRAGE with disease specific characteristics such as lung function and
DLCO, and with different circulating AGEs.
Methods: Plasma levels of esRAGE and sRAGE were measured in an 88 patients with COPD and in 55 healthy controls.
FEV1 (%predicted) and FEV1/VC (%) were measured in both groups; DLCO (%predicted) was measured in patients only.
In this study population we previously reported that the AGE Nε-(carboxymethyl) lysine (CML) was decreased, Nε-
(carboxyethyl) lysine (CEL) increased and pentosidine was not different in plasma of COPD patients compared to controls.
Results: Plasma esRAGE (COPD: 533.9 ± 412.4, Controls: 848.7 ± 690.3 pg/ml; p= 0.000) was decreased in COPD
compared to controls. No significant correlations were observed between plasma esRAGE levels and lung function
parameters or plasma AGEs. A positive correlation was present between esRAGE and total sRAGE levels in the circulation.
Confirming previous findings, total sRAGE (COPD: 512.6 ± 403.8, Controls: 1834 ± 804.2 pg/ml; p< 0.001) was lower in
patients compared to controls and was positively correlated FEV1 (r = 0.235, p = 0.032), FEV1/VC (r = 0.218, p = 0.047),
and DLCO (r = 0.308, p= 0.006). sRAGE furthermore did show a significant positive association with CML (r = 0.321,
p= 0.003).
Conclusion: Although plasma esRAGE is decreased in COPD patients compared to controls, only total sRAGE showed a
significant and independent association with FEV1, FEV1/VC and DLCO, indicating that total sRAGE but not esRAGE may
serve as marker of COPD disease state and severity.
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Chronic obstructive pulmonary disease (COPD) is a
major cause of morbidity and mortality. Long term in-
halation of noxious gases including cigarette smoke leads
to airflow obstruction and emphysema in the lungs. On
the other hand persistent systemic inflammation and
oxidative stress are common features of this disease.
Currently, soluble Receptor for Advanced Glycation End
products (sRAGE) is considered as a potential biomarker* Correspondence: ericarutten@ciro-horn.nl
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unless otherwise stated.for emphysema, based on data showing emphysema as
independent predictor of decreased levels of sRAGE in
the circulation of COPD patients [1,2].
RAGE is a transmembrane, multi ligand, pattern-
recognition receptor that belongs to the immunoglobulin
super family of cell surface receptors [3,4]. The human
RAGE gene (AGER) consisting of 11 exons, produces
membrane RAGE (mRAGE) which comprises an extracel-
lular, a transmembrane, and cytosolic domain. Alternative
splicing of the AGER gene leads to the formation of
endogenous soluble RAGE (esRAGE) [5]. On the other
hand, ectodomain shedding of mRAGE by metalloprotein-
ase such as MMP9 and A disintegrin and metalloproteasetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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uble forms of RAGE found in the circulation can act as
decoy receptors for Advanced Glycation Endproducts
(AGEs), preventing binding of AGEs to cell bound full
length RAGE and downstream activation of NF-kB [8].
Among many different extracellular ligands of RAGE,
we previously examined levels of three different protein-
bound AGEs in the plasma of COPD patients. In sum-
mary, Nε-(carboxymethyl) lysine (CML) was decreased,
Nε-(carboxyethyl) lysine increased and pentosidine was
not different in plasma of COPD patients compared to
controls [9]. Literature survey shows that among several
RAGE ligands investigated serum amyloid A (SAA),
S100 protein A12 (S100A12) and High- mobility group
protein B1 (HMGB1) were found to be increased in
COPD patients compared to controls [10,11].
Although plasma sRAGE is considered as a biomarker
for emphysema, no mechanisms have been proven to
date that underlie this association. The most straightfor-
ward mechanism is that the lower plasma level of
sRAGE is a reflection of the disappearance of pneumo-
cytes which typically display very high RAGE expression
[12]. A complicating factor is that it is assumed that the
major soluble form of RAGE in the circulation is
sRAGE. Recently however, a study identified an import-
ant contribution of esRAGE to total sRAGE as well as
positive correlations of esRAGE to total sRAGE in BAL
fluid and serum of asthmatics and COPD patients [13]
Unfortunately, this manuscript did not report on differ-
ences in esRAGE levels between COPD patients and
controls, or relations of esRAGE to disease markers.
In order to gain further evidence for plasma sRAGE as
a potential biomarker in COPD, we measured plasma
levels of esRAGE in patients with COPD and a control
group. Furthermore, we established possible relations of
esRAGE with different circulating AGEs, and disease
specific characteristics such as lung function, DLCO and
use of external oxygen. Circulating sRAGE levels were




The study population included 88 moderate to severe
COPD patients referred for pulmonary rehabilitation,
and 55 healthy controls who were recruited in Ciro+,
center of expertise for chronic organ failure, Horn, the
Netherlands. Clinical history of COPD and the degree of
disease severity were assessed according to the Global
Initiative for Chronic Obstructive disease guidelines
[14,15]. Exclusion criteria were history of tumor, dia-
betes, and an exacerbation of the disease for <4 weeks
before blood draw. Control subjects were judged healthy
by a standardized health questionnaire. This study wasapproved by the local medical ethical committee of
Maastricht University Medical Center, the Netherlands
and was supported by lung foundation Netherlands
under AF2009 project no: 3.2.09.049.
Patient consent
Patient consent: a written informed consent was taken
from all study participants for the sake of publication.
The number of pack years (PY; the number of packs
of cigarettes smoked per day divided by 20 multiplied by
the number of years smoked) and the smoking status
(never/ex-smoker) were recorded. People with 0 PY were
considered never smokers, and who stopped smoking at
least 1 year prior to recruitment was considered an ex-
smoker. Lung function was determined by spirometry,
and post-bronchodilator forced expiratory volume in
1 sec (FEV1) and forced vital capacity (FVC) were calcu-
lated from the flow-volume curve, and FEV1/VC was
calculated and expressed as%. Diffusion capacity of car-
bon monoxide (DLCO) was assessed by using single-
breath method (Masterlab®, Jaeger, Germany), expressed
as %predicted and used as an indirect marker for em-
physema [14,16,17]. Height and weight were measured
in every participant and body mass index (BMI) was cal-
culated (weight divided by height2 (kg/m2)). Use of long
term oxygen treatment (LTOT) was recorded in the
patients.
Blood collection and determination of plasma markers
Blood was collected in an evacuated tube containing
EDTA (Sherwood Medical, St Louis, Missouri, USA) and
immediately centrifuged at 800 rpm for 10 min at 4°C.
The plasma samples were subsequently stored at −80°C
until analysis. Plasma esRAGE (B-Bridge international
Inc., UK) and sRAGE (R&D systems, Minneapolis, USA)
were measured by ELISA. Plasma protein-bound CML
and CEL were measured by liquid chromatography tan-
dem mass spectrometry [18] and pentosidine was mea-
sured by HPLC with fluorescence detection [19] and
expressed per lysine concentrations. Plasma levels of
high density lipoproteins (HDL), triglycerides, glucose,
C–reactive protein (CRP) and creatinine were measured
in an auto-analyzer (ABX Pentra 400, HORIBA ABX
S.A.S, France). Glomerular filtration rate (GFR) was
calculated using the Cockcroft-Gault formula [20].
Statistical methods
SPSS (version 17, Chicago, IL) was used for data analysis.
Variables with skewed distribution like esRAGE, sRAGE,
CRP, FEV1, pentosidine and triglycerides were log trans-
formed before further analysis. Comparison of characteris-
tics between groups was performed by unpaired student’s
t or Chi-square tests, for continuous or categorical
data, respectively (Table 1). Spearman correlations were
Table 2 Correlations of sRAGE, esRAGE with AGEs in
COPD
esRAGE sRAGE
CML r = −0.034, p = 0.785 r = 0.321, p = 0.003
CEL r = −0.220, p = 0.076 r = −0.11, p = 0.921
pentosidine r = −0.032, p = 0.799 r = 0.106, p = 0.347
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sRAGE with AGEs (Table 2) and other measured parame-
ters (Tables 3 and 4). Uni- and multivariate linear regres-
sion analysis was used to investigate the association of
plasma esRAGE and sRAGE with lung function, DLCO
and LTOT. Primarily the parameters which showed a sig-
nificant or a relevant (age and sex) association with
esRAGE and sRAGE were included to build the regression
models. Because of the co-linearity of the lung function
parameters they were analyzed separately. All analysis
were first adjusted for age, sex and GFR (models 1 and 2),
next we evaluated the association of sRAGE and esRAGE
with FEV1 or FEV1/VC (model 3), with DLCO (model 4),
and with LTOT (model 5).
Results
General description of COPD and controls
Table 1 describes the baseline characteristics of the study
group. As expected, FEV1 was significantly lower in the
COPD patients compared to the never and ex-smoking
controls (p < 0.001). Based on the GOLD criteria 34Table 1 General characteristics of COPD patients and controls
Never smoker contro
n = 11
Age 58 ± 5.9
Male, (n)% (3) 27.3
Pack years* 0 ± 0
Smoking status, (n)%§ -
BMI, kg/m2 26.9 ± 4.0




Triglycerides, mg/dl 92.2 (85.1-109.0)
HDL, mg/dl 69.1 ± 14.3
CRP, mg/L 0.6 (0.1-0.9)
Medication use
Long/short acting muscarinic receptor antagonist (n)%
LABA, (n)%
SABA, (n)%





Unless otherwise stated all data are expressed as mean ± SD or median (IQR).
p-value <0.05 between COPD patients and ex-smoking controls is noted as E, and b
*indicates history of pack year smoked is missing for 34 patients; smoking stop date
§indicates smoking status of 6 patients were missing because of missing informatio
Abbreviations used: BMI, body mass index; FEV1, forced expiratory volume in 1 seco
beta agonists; SABA, short-acting beta agonists.patients were categorized GOLD II, 39 as GOLD III and
15 as GOLD IV. COPD patients had smoked more PY
compared to ex-smoking controls. Furthermore, no differ-
ences were observed in the plasma levels of HDL, triglyc-
erides, creatinine and GFR between patients and controls.
Lastly, CRP was found to be increased in COPD patients
compared to both control groups (p < 0.001).
Plasma esRAGE in COPD and controls
Plasma esRAGE levels were significantly decreased in
COPD patients compared to never and ex- smoking
controls [never smoker: 1098 ± 893; ex-smoker: 781 ±
626; COPD: 534 ± 412, pg/ml, (Figure 1A)]. No effect ofls, Ex-smoker controls,
n = 44
COPD, n = 88
61 ± 5.4 63 ± 8E,N
(22) 50 (46) 52.3
15.6 ± 13.3 35.0 ± 16.1E,N
- Ex-smoker (64) 72.7 Current smoker (18) 20.5
27.52 ± 4.0 26.1 ± 5.2
122.1 (112.0-133.0) 45.50 (32.3-61.0)E,N
78.9 (75.2-82.5) 51.9 (38.3-63.3)E,N
- 51.46 (42.4-73.19)
- 16
93.0 (71.8-135.6) 100.1 (84.2-136.9)
68.5 ± 20.5 75 ± 27









etween COPD and never smoking controls as N.
is available for this group.
n on pack years smoked or smoking stop date.
nd; HDL, high density lipoproteins; CRP, C- reactive protein; LABA, long-acting
Table 3 Linear regression analysis of COPD patients with
plasma esRAGE as dependent variable
Univariate analysis B 95% CI for B p value
Age 0.029 0.006 to 0.052 0.016
Sex −0.255 −0.637 to 0.127 0.187
Pack years 0.001 −0.012 to 0.014 0.925
BMI 0.022 −0.015 to 0.059 0.240
FEV1 0.007 −0.004 to 0.018 0.220
FEV1/VC 0.010 −0.002 to 0.022 0.108
LTOT 0.112 −0.418 to 0.642 0.674
CRP 0.015 −0.010 to 0.040 0.246
DLCO 0.012 −0.002 to 0.026 0.092
GFR −0.010 −0.019 to 0.000 0.042
Multivariate analysis B 95% CI for B p value
Model 1: Age + sex −0.363 −0.754 to 0.028 0.068
Model 2: model 1 + GFR −0.006 −0.015 to 0.004 0.271
Model 3: model 2 + FEV1 0.002 −0.011 to 0.015 0.784
Model 4: model 3 + DLCO 0.004 −0.004 to 0.026 0.157
Model 5: model 4 + LTOT −0.011 −0.665 to 0.644 0.974
Multivariate analysis B 95% CI for B p value
Model 1: Age + sex −0.265 −0.638 to 0.107 0.068
Model 2: model 1 + GFR −0.007 −0.019 to 0.006 0.287
Model 3: model 2 + FEV1/VC 0.007 −0.006 to 0.020 0.314
Model 4: model 3 + DLCO 0.009 −0.008 to 0.025 0.292
Model 5: model 4 + LTOT 0.009 −0.656 to 0.653 0.996
B is unstandardized coefficient.
Figure 1 Decreased plasma esRAGE levels in COPD patients
compared to controls (A) are not correlated to FEV1 (B) or
DLCO (C).
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esRAGE levels between never smoking controls and ex-
smoking controls, and between ex-smoking patients and
current smoking patients was not significant (p = 0.186
and p = 0.340 respectively). esRAGE furthermore was
not different between GOLD stages (GOLD II: 554.4 ±
340.8; GOLD III: 507.8 ± 468.6; GOLD IV:571.8 ± 393.2,
p = 0.871) and plasma esRAGE levels did not show a sig-
nificant correlation with FEV1 (Figure 1B), FEV1/VC
(data not shown), and DLCO (Figure 1C) in COPD
patients.
Plasma total sRAGE in COPD and controls
Plasma total sRAGE was also significantly decreased in
COPD patients compared to the never and ex-smoking
controls [never smoker: 2531 ± 1168; ex-smoker: 1671 ±
612; COPD: 512 ± 403 pg/ml, (Figure 2A)]. Plasma levels
of total sRAGE were in addition found to be significantly
lower in ex- compared to never-smoking controls (p =
0.047), indicating an effect of smoking per se. In COPD
patients on the other hand, no significant difference in
plasma sRAGE levels between ex-smokers and current
smokers was observed (p = 0.503). As previously shown,sRAGE was significantly different between GOLD stages
(GOLD II: 677.4 ± 576.8; GOLD III: 448.1 ± 241.7;
GOLD IV:350.8 ± 144.9, p = 0.013) and plasma total
sRAGE showed a positive correlation with FEV1 (r =
0.235, p = 0.032 (Figure 2B)) in COPD patients. A simi-
lar correlation was furthermore observed for FEV1/VC
Figure 2 Decreased plasma sRAGE levels in COPD patients
compared to controls (A) are correlated with FEV1 (B) and
DLCO (C).
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as for DLCO (r = 0.308, p = 0.006 (Figure 2C)).
Correlations of esRAGE, sRAGE, AGEs and CRP
As expected, plasma esRAGE levels were positively cor-
related with total sRAGE levels. This correlation was
found to be significant in the total study group (r = 0.436,p < 0.0001, Additional file 2: Figure S2), as well as in the
COPD patients (r = 0.361, p < 0.001, Additional file 3:
Figure S3b), and in healthy controls (r = 0.345, p = 0.016,
Additional file 3: Figure S3a) individually.
No significant correlations were observed between
plasma esRAGE levels and levels of AGEs in plasma.
Plasma total sRAGE on the other hand was found to be
positively correlated with plasma CML in COPD patients
(r = 0.321, p = 0.003 (Table 2)), but not in control subjects.
Plasma CEL and pentosidine were furthermore not signi-
ficantly associated with total sRAGE levels. In addition,
neither esRAGE nor total sRAGE showed a significant
correlation with plasma CRP (data not shown).Association of plasma esRAGE and sRAGE with lung
function, DLCO and LTOT
Table 3 represents the outcome of the univariate analysis
taking plasma esRAGE as dependent variable. Only age
demonstrated a significant positive and GFR a significant
negative association with plasma esRAGE levels. Multi-
variate analysis performed as outlined in Table 3, intro-
ducing either FEV1 or FEV1/FVC after correcting for
age, sex and GFR as common confounders, demonstrate
that the decrease in plasma esRAGE levels in COPD was
not determined by any of the disease severity markers
examined.
Similar uni- and multivariate analyses were performed
for plasma total sRAGE. Results of the univariate analyses
in Table 4 indicate significant positive associations of total
sRAGE with FEV1, FEV1/VC, and DLCO, and a negative
association with LTOT. These variables were next used in
multivariate analysis including age and sex as common
confounders (model 1). Using this model, FEV1 showed
a significant positive association with sRAGE [B: 0.010
(95% CI: 0.003 to 0.017); p = 0.006)]. When DLCO was
introduced in the model the association remained with
statistical significance (model 3, Table 4). However, when
LTOT (as a dichotomous variable) was added to the
model the direction of the association changed in con-
junction with a stronger B value [model 2, B: -0.414
(95% CI: -0.781to −0.047); p = 0.028). A similar analysis
was performed separately for FEV1/VC resulting in
similar outcomes (Table 4).Discussion
The present study demonstrates decreased levels of
esRAGE and total sRAGE in plasma of COPD patients
compared to controls. Importantly, in COPD, total sRAGE
and not esRAGE showed positive associations with FEV1,
FEV1/VC, and DLCO, and only sRAGE levels were nega-
tively and independently associated with LTOT. Further,
only total sRAGE levels were positively associated with
CML, a major ligand of RAGE.
Table 4 Linear regression analysis of COPD patients with
plasma sRAGE as dependent variable
Univariate analysis B 95% CI for B p value
Age 0.010 −0.005 to 0.025 0.190
Sex −0.076 −0.325 to 0.173 0.547
Pack years 0.002 −0.006 to 0.010 0.630
BMI −0.008 −0.032 to 0.015 0.480
FEV1 0.010 0.003 to 0.017 0.007
FEV1/VC 0.012 0.004 to 0.019 0.004
LTOT −0.329 −0.640 to −0.017 0.039
GFR −0.006 −0.011 to 0.000 0.069
CRP −0.004 −0.019 to 0.011 0.584
DLCO 0.014 0.006 to 0.023 0.002
Multivariate analysis B 95% CI for B p value
Model 1: Age + sex −0.096 −0.345 to 0.153 0.444
Model 2: model 1 + FEV1 0.010 0.003 to 0.017 0.006
Model 3: model 2 + DLCO 0.012 0.002 to 0.022 0.017
Model 4: model 3 + LTOT −0.414 −0.781 to −0.047 0.028
Multivariate analysis B 95% CI for B p value
Model 1: Age + sex −0.96 −0.346 to 0.153 0.444
Model 2: model 1 + FEV1/VC 0.012 0.004 to 0.019 0.004
Model 3: model 2 + DLCO 0.011 0.001 to 0.021 0.026
Model 4: model 3 + LTOT −0.427 −0.787 to −0.066 0.021
B is unstandardized coefficient.
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measured using a commercially available ELISA that de-
tects total sRAGE, thus including esRAGE. Only one re-
cent publication measured esRAGE separately in COPD.
This study identified an important contribution of esRAGE
to total sRAGE and positive correlations of esRAGE to
sRAGE in BAL fluid and serum of asthmatics and COPD
patients [13]. However, it did not report on differences in
esRAGE levels between patients and controls, or relations
to disease markers. Data from the present study confirm a
moderate positive correlation of plasma esRAGE with total
sRAGE levels and for the first time demonstrate decreased
plasma esRAGE levels in COPD.
Two different mechanisms producing total sRAGE are
by alternative splicing of AGER gene which results in se-
cretion esRAGE, and by ectodomain shedding of mem-
brane RAGE by MMP9/ADAM10 which leads to the
secretion of sRAGE [21]. Both esRAGE and total sRAGE
were observed to be lower in the circulation of COPD
patients. Smoking per se seemed to affect total sRAGE
levels as there was a significant difference between never
and ex-smoking controls. This was however not the case
for esRAGE (Figures 2A and 1A respectively), indicating
that smoking affects shedding but not alternative spli-
cing. Still it is important to further evaluate the effect ofsmoking as a cause for decreased sRAGE/esRAGE. Fur-
thermore, the pattern of plasma sRAGE and esRAGE
levels in the circulation of individual COPD patients and
controls were found to be different. Based on these
findings it is difficult to conclude whether alternative
splicing or shedding or both are operational, since there
is no literature on altered AGER gene expression and
ADAM10 in the pulmonary/extra pulmonary compart-
ment in COPD. However there is evidence in the litera-
ture of increased MMP9 protein levels in BAL of COPD
patients [22,23], whereas an absence of difference in
MMP9 levels and activity in the circulation of COPD pa-
tients was reported [24]. Further research is needed to
determine whether altered gene expression, alternative
splicing, and/or sheddases activity are responsible for de-
creased sRAGE levels in circulation.
Lowered levels of both esRAGE and sRAGE in the circu-
lation of COPD patients could also be associated with the
presence of functional single nucleotide polymorphisms
(SNPs) in the AGER gene. Sequence variation studies have
shown that there are 50 SNPs in 11 exons and 10 introns
in the AGER gene. Among them rs2070600 [15] was asso-
ciated with lower levels of plasma sRAGE in patients with
diabetes and also in COPD [25,26]. Information regarding
associations of circulating esRAGE levels with polymor-
phisms is limited. In type 2 diabetes it has been shown that
rs2070600 and rs1800625 are associated with esRAGE
levels in a Chinese cohort [27]. Given these genetic associ-
ations to circulating sRAGE levels in diseases affecting
different primary organs and the contrasting increased pul-
monary expression of RAGE in COPD patients, it remains
questionable if lower systemic sRAGE levels indeed arise
from altered pulmonary levels, and if so how [26,28].
There is one recent manuscript showing no decrease in
plasma sRAGE level in patients with COPD with or with-
out chronic heart failure [29], findings that are in contrast
with many others, including our own showing decreased
plasma total sRAGE levels in COPD [1,10,30].
Findings of the study presented here are in line with lit-
erature showing that plasma total sRAGE levels are associ-
ated with lung function in COPD [1,10,30,31]. In addition
we evaluated whether comparable trends could be observed
for esRAGE as both receptors have similar structures and
functions, originating from the same gene through different
mechanisms. In contrast to total sRAGE, we did however
not find significant associations of plasma esRAGE with
lung function parameters. Although the lack of CT data is
a limitation of the current study, the finding that DLCO in
most previous studies also correlated with plasma sRAGE
levels, was replicated here as well. In addition we provide
evidence that plasma total sRAGE levels are associated with
the use of LTOT, even after adjustment for possible con-
founders and lung function. Again, such association with
DLCO or oxygen use was not present for esRAGE. The
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COPD patients, and its association to alveolar damage is
still not clear. From the results of the present study we can
concluded that total sRAGE and not esRAGE resulting
from splice variation of the AGER gene contributes to this
association. Mechanisms involved in shedding of the recep-
tor are likely involved, including via activation of sheddases
like ADAM10 and MMP9, or via ligand engagement.
We investigated correlations of total sRAGE and
esRAGE with measured plasma AGEs. The only signifi-
cant correlation observed was between sRAGE and CML.
RAGE ligands other than AGEs have been measured in
the systemic circulation of patients with COPD. HMGB1,
S100A12and SAA were found to be increased in COPD
[10,11,32], Among these ligands, only SAA showed a
negative association with sRAGE. We previously reported
decreased plasma CML levels in COPD and we showed
here that this is positively correlated with sRAGE. Acce-
lerated formation and accumulation of AGEs is due to
inflammation and oxidative stress [33]. However, we previ-
ously found that alterations in plasma levels of CML were
independent of CRP, as a marker of inflammation [9].
With our previous [30] and present data we furthermore
did not find significant correlations of either sRAGE or
esRAGE with CRP. Only one study was able to demon-
strate a negative association of sRAGE with CRP in COPD
[10], but a clear relationship between sRAGE and inflam-
mation and oxidative stress has not been found so far. Fur-
ther investigations are clearly needed that assess the
association of sRAGE/esRAGE with comprehensive panels
of RAGE ligands as well as inflammatory markers in large
cohorts of patients.
In contrast to the recent attention given to sRAGE in
lung research, little is known about the role of esRAGE in
pulmonary physiology and pathology. It has been shown
that not only vascular endothelial cells express esRAGE,
but also neuronal, thyroid follicular, hepatocytes and pan-
creatic beta cells could be a possible source of circulating
esRAGE [34]. Plasma levels are in addition determined by
excretion via the kidneys. Plasma esRAGE is known to be
strongly affected by renal insufficiency [35]; in agreement
we observe a significant negative correlation of esRAGE
with GFR. The current study shows decreased esRAGE
levels in COPD, but no associations with disease charac-
teristics. The observed decrease in esRAGE levels in
COPD is important for future investigations into molecu-
lar mechanism behind the decreased levels of total sRAGE
demonstrated often already and proposed as a biomarker
for the disease, but still warrants further confirmation.
Secondly, to establish whether systemic sRAGE alterations
are causatively related to the development of structural
emphysema or a systemically reflective consequence fur-
ther longitudinal research is warranted in non-obstructed
cigarette smokers.In summary, both esRAGE and sRAGE are decreased
in the circulation of COPD patients compared to con-
trols. Only sRAGE showed a positive association with
lung function and DLCO, a negative association with
CML and was affected by oxygen treatment in COPD.
We conclude that, although these molecules are prod-
ucts of the same gene they may have different roles in
the pathogenesis of COPD and that primarily total
sRAGE is a candidate biomarker for COPD phenotypes.
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Additional file 1: Figure S1. Plasma sRAGE levels in COPD correlated
with FEV1/VC.
Additional file 2: Figure S2. Plasma levels of sRAGE and esRAGE in
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Additional file 3: Figure S3. Decreased plasma esRAGE compared to
sRAGE in (a) controls (b) COPD patients.
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